Exchange: NASDAQ·Updated 04:25 PM EST

CRDF News

News
all
press releases
HC Wainwright Analysts Increase Earnings Estimates for CRDF
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Stock analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for shares of Cardiff Oncology in a report issued on Monday, November 16th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings...
MarketBeat
HC Wainwright Analysts Increase Earnings Estimates for CRDF
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Stock analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for shares of Cardiff Oncology in a report issued on Monday, November 16th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings...
MarketBeat
More News
Cardiff Oncology, Inc. (CRDF) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript...
SeekingAlpha
Thanksgiving is approaching, and small-cap traders have a full plate of developments to follow. The names include Cyabra (NASDAQ:CYAB), Kraig Biocraft Laboratories (OTCQB:KBLB), Polar Power (NASDAQ:POLA), Robin Energy (NASDAQ:RBNE), Generation Income Properties (NASDAQ:GIPR), Cardiff Oncology (NASDAQ:CRDF), Haoxin Holdings (NASDAQ:HXHX) and Sable Offshore (NYSE:SOC).
24-7 Market News
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential...
Yahoo! Finance: News
Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.read more...
Benzinga
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has ass...
MarketBeat
Cardiff Oncology (NASDAQ:CRDF) Stock Price Down 1.1% - Here's Why...
MarketBeat
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Research analysts at Noble Financial raised their Q1 2026 earnings per share (EPS) estimates for shares of Cardiff Oncology in a note issued to...
MarketBeat
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat...
MarketBeat
Cardiff Oncology (NASDAQ:CRDF) interim CEO Mani Mohindru outlined updated clinical results and development plans for the company's investigational PLK1 inhibitor onvansertib during a webinar focused...
MarketBeat

Advertisement|Remove ads.